11
Nov
Mumbai (Maharashtra) [India], November 11: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), is one of the Leading Pharmaceuticals Formulation manufacturing companies in India. Diversified into Generics, Cosmeceuticals, Nutraceuticals, Mobility and animal healthcare products, has reported its Unaudited financials for Q2 FY26 & H1 FY26. Key Financial Highlights Q2 FY26 Standalone Financial Highlights • Total Income of ₹ 145.29 Cr, YoY growth of 35.34% • EBITDA of ₹ 22.34 Cr, YoY growth of 60.09% • EBITDA Margin (%) of 15.37%, YoY growth of 238 Bps • Net Profit of ₹ 9.73 Cr, YoY growth of 127.75% • Net Profit Margin (%) of 6.70%, YoY growth of 272 Bps • EPS of ₹ 20.61, YoY growth of 127.73% H1…
